October 1st 2025
Patient response focused on perceived vision-related quality of life outcomes, investigators said
September 24th 2025
Outcomes with Raricimab and Choosing Between the New Therapies
February 7th 2025Panelists discuss how faricimab’s dual inhibition of Ang-2 provides additional benefits in vascular stability and inflammation reduction beyond VEGF-A suppression alone, potentially leading to improved durability and treatment outcomes in selected patients.
Patient Selection for Aflibercept 8 mg
January 31st 2025Panelists discuss how ideal candidates for aflibercept 8 mg include patients with stable disease on current anti-VEGF therapy who seek reduced treatment burden, newly diagnosed patients, and those demonstrating good response to initial loading doses.
Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg
January 24th 2025Panelists discuss how the phase 3 PULSAR and PHOTON trials demonstrated the efficacy of aflibercept 8 mg through a design comparing 12- and 16-week dosing intervals to the aflibercept 2 mg standard 8-week dosing, with primary end points assessing noninferiority in visual acuity maintenance.